CGC - Will Biden's Shaky Debate Performance Affect Cannabis Reform? How A Trump Return Could Reshape Marijuana Policy | Benzinga
President Joe Biden's shaky debate performance this week is stirring doubts among Democrats about his viability for reelection.
As doubts about the president's electability circulate, questions
around federal cannabis reform anticipated under Biden's administration are also swirling.
How would a return of Donald Trump to the White House influence the future of cannabis legalization?
How Severe Were The Losses? Cannabis Stocks Ranked By Decline In Benzinga Pro
Following Biden's debate performance, major cannabis stocks experienced significant declines, ranked here from the largest to smallest losses. Trulieve Cannabis Corp (OTC: TCNNF) led the downturn with an 11.99% drop followed by Curaleaf Holdings (OTC: CURLF) which fell 10.54%.
The AdvisorShares Pure US Cannabis ETF (NYSE: MSOS) decreased by 8.83%, and Green Thumb Industries (OTC: GTBIF) saw a 6.33% decline. The AdvisorShares Pure Cannabis ETF (NYSE: YOLO) dropped by 5.16%, and Tilray Brands (NASDAQ: TLRY) by 4.05%.
Canopy Growth Corporation (NASDAQ: CGC) decreased by 3.30%, OrganiGram Holdings Inc. (NASDAQ: OGI) by 3.75%, and Aurora Cannabis (NASDAQ: ACB) by 2.33%. Cronos Group (NASDAQ: CRON) had the smallest decline at 0.43%.
These investing issues will be a hot topic at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the industry. Hear directly from top executives, investors, advocates, and policymakers.